DURECT (DRRX) - 2024 Q3 - Quarterly Results

Exhibit 99.1 DURECT Corporation Reports Third Quarter 2024 Financial Results and Provides Business Update - Seeking to initiate Phase 3 registrational trial for larsucosterol with topline results expected within two years of initiation - Webcast of Earnings Call Today, November 13 at 4:30 p.m. ET CUPERTINO, Calif., November 13, 2024 /PRNewswire / -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended September 30, 2024 and provided a business update. "We remain foc ...